Literature DB >> 32160073

Multimodal Imaging in Ocular Toxoplasmosis.

Camilo Brandão-de-Resende1,2, Manohar Babu Balasundaram3, Shishir Narain4, Padmamalini Mahendradas5, Daniel V Vasconcelos-Santos1,2,6.   

Abstract

Multimodal imaging relies on combination of multiple imaging modalities to precisely delineate pathological changes in the posterior segment of the eye associated with a wide range of conditions. This combined application of fundus photography, optical coherence tomography, fundus reflectance/autofluorescence and fundus angiography (with fluorescein, indocyanine green and/or optical coherence tomography) is of great utility for assessment of patients with ocular toxoplasmosis. Multimodal imaging is helpful to characterize the typical pattern of toxoplasmic retinochoroiditis, with primary focal inflammatory involvement of the neurosensory retina, and secondary changes at the level of underlying choroid, retinal blood vessels, vitreous and even optic disc. It may also be valuable to document and follow local complications, including macular edema, vascular occlusions, and choroidal neovascularization, among others.

Entities:  

Keywords:  Ocular toxoplasmosis; angiography; diagnosis; imaging; optical coherence tomography; uveitis

Year:  2020        PMID: 32160073     DOI: 10.1080/09273948.2020.1737142

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Distinguishing swept-source optical coherence tomography findings in active toxoplasmic retinochoroiditis.

Authors:  Imen Ksiaa; Sana Khochtali; Mossaab Mefteh; Manel Ben Fredj; Hajer Ben Amor; Nesrine Abroug; Moncef Khairallah
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 4.456

2.  In vitro and in vivo anti-Toxoplasma activities of HDAC inhibitor Panobinostat on experimental acute ocular toxoplasmosis.

Authors:  Yu Zhang; Qingqing Zhang; Haiming Li; Hua Cong; Yi Qu
Journal:  Front Cell Infect Microbiol       Date:  2022-09-12       Impact factor: 6.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.